Evidence map›Paper›PMID 33671551›Full record

ArticleCancers2021

Picturing Breast Cancer Brain Metastasis Development to Unravel Molecular Players and Cellular Crosstalk.

Inês Figueira, Sofia Galego, Tânia Custódio-Santos, Raquel Vicente, Kinga Molnár, Janos Haskó, Rui Malhó, Mafalda Videira, Imola Wilhelm, István Krizbai and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Organ-Specificity of Breast Cancer Metastasis.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. The Journey of Cancer Cells to the Brain: Challenges and Opportunities.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Inês FigueiraFarm-ID-Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento, 1649-003 Lisbon, Portugal.ORCID 0000-0003-4639-6883
Sofia GalegoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Tânia Custódio-SantosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Raquel VicenteResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Kinga MolnárInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), 6726 Szeged, Hungary.ORCID 0000-0002-0596-2191
Janos HaskóInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), 6726 Szeged, Hungary.
Rui MalhóBioISI, BioSystems and Integrative Sciences Institute, Faculty of Sciences, Universidade de Lisboa, 1749-016 Lisbon, Portugal.
Mafalda VideiraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Imola WilhelmInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), 6726 Szeged, Hungary.ORCID 0000-0003-2366-7337
István KrizbaiInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), 6726 Szeged, Hungary.
Maria Alexandra BritoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0002-8493-4649
University of Lisbon · PTHUN-REN Szegedi Biológiai Kutatóközpont · HU

Funding

Fundação para a Ciência e a Tecnologia PTDC/MED-ONC/29402/2017, UIDB/04138/2020 and UIDP/04138/2020, and 441.00 HUNGRIANational Research, Development and Innovation Office FK-124114, K-135425, K-135475, GINOP-2.3.2-15-2016-00020 and GINOP-2.3.2-15-2016-00034The New National Excellence Program of the Ministry for Innovation and Technology ÚNKP-20-4-SZTE-138Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii PN-III-P1-1.1-TE-2019-1302 and PN-III-P4-ID-PCE-2020-1529
6 · The paper itself

Abstract

With breast cancer (BC) therapy improvements, the appearance of brain metastases has been increasing, representing a life-threatening condition. Brain metastasis formation involves BC cell (BCC) extravasation across the blood-brain barrier (BBB) and brain colonization by unclear mechanisms. We aimed to disclose the actors involved in BC brain metastasis formation, focusing on BCCs' phenotype, growth factor expression, and signaling pathway activation, correlating with BBB alterations and intercellular communication. Hippocampi of female mice inoculated with 4T1 BCCs were examined over time by hematoxylin-eosin, immunohistochemistry and immunofluorescence. Well-established metastases were observed at seven days, increasing thereafter. BCCs entering brain parenchyma presented mesenchymal, migratory, and proliferative features; however, with time, they increasingly expressed epithelial markers, reflecting a mesenchymal-epithelial transition. BCCs also expressed platelet-derived growth factor-B, β

Indexed as

blood–brain barrierbreast cancer brain metastasisextravasationintercellular communicationmesenchymal–epithelial transitionmicrovasculature

Identifiers

PMID33671551
PMCPMC7926545
OpenAlexW3132205930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.